Novo Integrated Sciences (NVOS) 10-K 9 Dec 20 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2020	Dec. 07, 2020	Feb. 28, 2020
Cover [Abstract]
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Document Type	10-K
Document Period End Date	Aug. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 17,071,387
Entity Common Stock, Shares Outstanding		235,531,411
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Current Assets:
Cash and cash equivalents	$ 2,067,718	$ 2,083,666
Accounts receivable, net	1,732,432	1,463,529
Other receivables, current portion	302,664	300,994
Prepaid expenses and other current assets	191,723	250,398
Total current assets	4,294,537	4,098,587
Property and equipment, net	353,660	410,188
Intangible assets, net	26,623,448	22,358,567
Right-of-use assets	2,810,556	3,004,017
Other receivables, net of current portion	287,775	1,062,241
Acquisition deposits	383,700	716,688
Goodwill	636,942	623,081
TOTAL ASSETS	35,390,618	32,273,369
Current Liabilities:
Accounts payable	883,773	1,144,812
Accrued expenses	194,708	205,784
Accrued interest (principally to related parties)	346,264	248,582
Government loans and note payable	83,292
Due to related parties	528,213	920,083
Operating lease liability, current portion	563,793	508,305
Total current liabilities	2,600,043	3,027,566
Debentures, related parties	952,058	1,201,591
Operating lease liability, net of current portion	2,266,887	2,500,004
TOTAL LIABILITIES	5,818,988	6,729,161
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at August 31, 2020 and 2019
Common stock; $0.001 par value; 499,000,000 shares authorized; 234,662,363 and 223,691,507 shares issued and outstanding at August 31, 2020 and 2019, respectively	234,662	223,691
Additional paid-in capital	44,694,258	35,813,203
Other comprehensive income	1,199,696	1,138,919
Accumulated deficit	(16,507,127)	(11,591,973)
Total Novo Integrated Sciences, Inc. stockholders' equity	29,621,489	25,583,840
Noncontrolling interest	(49,859)	(39,632)
Total stockholders' equity	29,571,630	25,544,208
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 35,390,618	$ 32,273,369

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2020	Aug. 31, 2019
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	234,662,363	223,691,507
Common stock, shares outstanding	234,662,363	223,691,507

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Statement [Abstract]
Revenues	$ 7,860,567	$ 9,421,825
Cost of revenues	4,802,195	5,902,381
Gross profit	3,058,372	3,519,444
Operating expenses:
Selling expenses	4,921	39,931
General and administrative expenses	7,286,305	4,019,865
Write down of assets	29,744	245,245
Total operating expenses	7,320,970	4,305,041
Loss from operations	(4,262,598)	(785,597)
Non operating income (expense)
Interest income	33,627	154,793
Interest expense	(156,662)	(222,155)
Other income (expense)	(194,055)	72,080
Gain on settlement of debt		377,300
Write off of acquisition deposit	(344,521)
Total other income (expense)	(661,611)	382,018
Loss before income taxes	(4,924,209)	(403,579)
Income tax expense
Net loss	(4,924,209)	(403,579)
Net loss attributed to noncontrolling interest	(9,055)	(11,595)
Net loss attributed to Novo Integrated Sciences, Inc.	(4,915,154)	(391,984)
Comprehensive loss:
Net loss	(4,924,209)	(403,579)
Foreign currency translation gain (loss)	60,777	(896)
Comprehensive loss:	$ (4,863,432)	$ (404,475)
Weighted average common shares outstanding - basic and diluted	230,340,805	217,322,628
Net loss per common share - basic and diluted	$ (0.02)	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total Novo Stockholders' Equity [Member]	Noncontrolling Interest [Member]	Total
Balance at Aug. 31, 2018	$ 207,882	$ 10,053,683	$ 1,139,815	$ (11,199,989)	$ 201,391	$ (28,621)	$ 172,770
Balance, shares at Aug. 31, 2018	207,881,743
Common stock issued for cash	$ 3,266	3,247,100			3,250,366		3,250,366
Common stock issued for cash, shares	3,266,857
Common stock issued for interest in joint venture	$ 12,000	21,588,000			21,600,000		21,600,000
Common stock issued for interest in joint venture, shares	12,000,000
Common stock issued for software license	$ 458	758,109			758,567		758,567
Common stock issued for software license, shares	458,349
Common stock issued for acquisition	$ 85	95,465			95,550		95,550
Common stock issued for acquisition, shares	84,558
Fair value of vested stock options		70,846			70,846		70,846
Foreign currency translation loss			(896)		(896)	584	(312)
Net loss				(391,984)	(391,984)	(11,595)	(403,579)
Balance at Aug. 31, 2019	$ 223,691	35,813,203	1,138,919	(11,591,973)	25,583,840	(39,632)	25,544,208
Balance, shares at Aug. 31, 2019	223,691,507
Common stock issued for cash	$ 355	113,044			113,399		113,399
Common stock issued for cash, shares	354,369
Common stock issued for software license	$ 965	385,266			386,231		386,231
Common stock issued for software license, shares	965,578
Fair value of vested stock options		2,265,211			2,265,211		2,265,211
Common stock issued for licensing agreement	$ 8,000	5,240,000			5,248,000		5,248,000
Common stock issued for licensing agreement, shares	8,000,000
Common stock issued for conversion of related party debt	$ 151	226,212			226,363		226,363
Common stock issued for conversion of related party debt, shares	150,909
Common stock issued for services	$ 1,500	588,500			590,000		590,000
Common stock issued for services, shares	1,500,000
Fair value of modification of stock option terms		62,822			62,822		62,822
Foreign currency translation loss			60,777		60,777	(1,172)	59,605
Net loss				(4,915,154)	(4,915,154)	(9,055)	(4,924,209)
Balance at Aug. 31, 2020	$ 234,662	$ 44,694,258	$ 1,199,696	$ (16,507,127)	$ 29,621,489	$ (49,859)	$ 29,571,630
Balance, shares at Aug. 31, 2020	234,662,363

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,924,209)	$ (403,579)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,445,076	97,143
Fair value of vested stock options	2,265,211	70,846
Expense associated with modified stock option terms	62,822
Common stock issued for services	590,000
Operating lease expense	541,530	214,893
Gain on settlement of debt		(377,300)
Write down of assets	29,744	245,245
Loss on settlement of other receivable	74,360
Write off of acquisition deposit	344,521
Changes in operating assets and liabilities:
Accounts receivable	(229,015)	(151,254)
Prepaid expenses and other current assets	61,218	(91,097)
Accounts payable	(275,895)	(140,093)
Accrued expenses	(15,591)	(172,309)
Accrued interest	114,815	95,815
Operating lease liability	(526,281)	(210,578)
Net cash used in operating activities	(441,694)	(822,268)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(12,110)	(107,635)
Payment for acquisition deposit	(636,985)	(377,300)
Cash paid for acquisition of assets		(132,055)
Amounts loaned for other receivables		(225,924)
Collection of other receivable	669,240
Return of acquisition deposit	636,985
Net cash provided by (used in) investing activities	657,130	(842,914)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties	(198,778)	(176,655)
Repayments of debenture, related party	(267,696)
Proceeds from government loans and note payable	81,388
Proceeds from the sale of common stock	113,399	3,250,366
Net cash provided by (used in) financing activities	(271,687)	3,073,711
Effect of exchange rate changes on cash and cash equivalents	40,303	(568)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(15,948)	1,407,961
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	2,083,666	675,705
CASH AND CASH EQUIVALENTS, END OF YEAR	2,067,718	2,083,666
CASH PAID FOR:
Interest	95,219	129,459
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for intangible assets	5,634,231	22,358,567
Common stock issued for debt	226,363
Common stock issued for acquisition of assets		$ 95,550

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Aug. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which deliver, or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science. Currently, the Company’s revenue is generated solely through its wholly owned Canadian subsidiary, Novo Healthnet Limited (“NHL”), which provides services and products through both clinic and eldercare related operations. Through NHL’s 16 corporate-owned clinics, a contracted network of 95 affiliate clinics and 220 eldercare related long-term care homes, retirement homes and community-based locations in Canada, our team of multidisciplinary primary health care clinicians and practitioners provide assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations.Our specialized multidisciplinary primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs including event and game coverage, and private personal training. Our clinicians and practitioners provide certain multidisciplinary primary health care services, and related products, beyond the medical doctor first level contact identified as primary care. Our clinicians and practitioners are not licensed medical doctors, physicians, specialist, nurses or nurse practitioners. Our clinicians and practitioners are not authorized to practice primary care medicine and they are not medically licensed to prescribe pharmaceutical based product solutions. Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) NHL, (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”) and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated’s common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Novo Integrated common stock, representing 85% of the issued and outstanding Novo Integrated common stock, calculated including all granted and issued options or warrants to acquire Novo Integrated common stock as of the Effective Date, but to exclude shares of Novo Integrated common stock that are subject to a then-current Regulation S offering that was undertaken by Novo Integrated (the “Exchange”). On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904. On November 3, 2017, Novomerica Health Group, Inc. (“Novomerica”) was incorporated, under the laws of the state of Nevada, as a wholly owned subsidiary of the Company for the purpose of expanding the Company’s operations into the United States. On January 7, 2019, 2478659 Ontario Ltd. (“247”) and Kainai Cooperative (“Kainai”) entered into a Joint Venture Agreement (the “Joint Venture Agreement”) for the purpose of developing, managing and arranging for financing of greenhouse and farming projects involving hemp and cannabis cash crops on Kainai related lands, and developing additional infrastructure projects creating jobs and food supply to local communities. On January 8, 2019, we and 247 entered into an Agreement of Transfer and Assignment, pursuant to which 247 agreed to sell, assign and transfer to the Company all rights, contracts, contacts and any and all other assets related in any way to the Joint Venture Agreement. Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai. The Joint Venture Agreement has an initial term of 50 years and Kainai may renew the Joint Venture Agreement within five years of the expiry of the initial term upon mutual agreement. On January 30, 2019, pursuant to the terms of the Joint Venture Agreement, the Company issued 12,000,000 restricted common shares to 247 with a value of $21,600,000. On February 26, 2019, the Company entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”) pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”) to include the: ● Cloud DX Connected Health web portal for clinical users, ● Cloud DX Connected Health mobile app, ● Cloud DX Connected Health Windows app, and ● Cloud DX Connected Health MacOS app. On July 22, 2019, the Company, through NHL, acquired substantially all the assets of Societe Professionnelle de Physiotherapie M Dignard, doing business as Action Plus Physiotherapy Rockland, to expand our corporate owned clinic footprint in the province of Ontario Canada. On September 24, 2019, Novomerica, a wholly owned U.S. based subsidiary of the Company, entered into a Master Facility License Agreement with Fitness International, LLC and Fitness & Sports Clubs, LLC (together with Fitness International, LLC, “LA Fitness U.S.”). On February 24, 2020, this Master Facility License Agreement (the “LA Fitness U.S. Agreement”) was amended pursuant to the terms of that certain First Amendment to the LA Fitness U.S. Agreement. On September 24, 2019, NHL entered into a Master Facility License Agreement with LAF Canada Company (“LA Fitness Canada”). On February 24, 2020, this Master Facility License Agreement (the “LA Fitness Canada Agreement”) was amended pursuant to the terms of that certain First Amendment to the LA Fitness Canada Agreement. On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell, proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada. Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 8,000,000 shares of restricted common stock of the Company. On December 19, 2019, the Company entered into that certain Joint Venture Agreement (the “HGF JV Agreement”) between the Company and Harvest Gold Farms Inc. (“HGF”) relating to the development, management and arrangement of medicinal farming projects involving hemp and cannabis cash crops (the “Project”). Pursuant to the terms of the HGF JV Agreement, the parties agreed to work in a joint venture relationship, with the Company providing the development and operation of the Project, including sales, and HGF providing the land, farming expertise, biomass and necessary approvals for the development of the Project. Pursuant to the terms of the HGF JV Agreement, a corporation, namely, Novo Earth Therapeutics Inc. was formed where we have a 70% controlling interest. The initial term of the HGF JV Agreement will, unless sooner terminated by consent of all parties, expire in five years from the effective date of the HGF JV Agreement. The Company and HGF may renew the HGF JV Agreement within two years of the expiration of the initial term upon mutual understanding. Impact of COVID-19 In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally. On March 17, 2020, as a result of COVID-19 infections having been reported throughout both Canada and the United States, certain national, provincial, state and local governmental issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Accordingly, on March 17, 2020, the Company closed all corporate clinics for all in-clinic non-essential services to protect the health and safety of its employees, partners and patients. On March 20, 2020, the Company announced the precautionary measures taken as well as announcing the business impact related to the coronavirus (COVID-19) pandemic. Operating under COVID-19 related governmental proclamations and directives, between March 17, 2020 and June 1, 2020, the Company provided in-clinic multi-disciplinary primary healthcare services and products solely to patients with emergency and essential need while also providing certain virtual based services related to physiotherapy. In light of most eldercare related services being deemed essential by national, provincial and local governmental authorities in Canada, NHL’s contracted eldercare related services have been nominally impacted during the fiscal third quarter and we project the same for the fiscal fourth quarter. On May 26, 2020, the Ontario Ministry of Health announced updated guidance and directives stating that physiotherapists, chiropractors and other regulated health professionals, including all services and products provided by the Company, can gradually and carefully begin providing all services, including non-essential services, once the clinician and provider are satisfied all necessary precautions and protocols are in place to protect the patients, the clinician and the clinic staff. With all corporate clinics closed due to the COVID-19 pandemic, with the exception of providing certain limited essential and emergency services, the Company had furloughed 48 full-time employees and 35 part-time employees from its pre-closure levels of 81 full-time employees and 53 part-time employees. On June 2, 2020, the Company commenced opening its corporate clinics and providing non-essential services. As of June 9, 2020, the Company had opened all corporate clinics while following all mandated guidelines and protocols from Health Canada, the Ontario Ministry of Health, and the respective disciplines’ regulatory Colleges to ensure a safe treatment environment for our staff and clients. Certain of these guidelines and protocols include both active and passive screening for staff and clients, enhanced cleaning measures using only Health Canada approved disinfectants and sanitizers, personal protective equipment usage, appropriate signage and markers throughout the clinics, and layout changes to the clinics to reflect proper physical distancing measures. Additional, more restrictive proclamations and/or directives may be issued in the future. As of July 10, 2020, the Company had increased staffing to 51 full-time employees and 24 part-time employees. With our clinics re-opened and operating under COVID-19 pandemic related mandated guidelines and protocols, as of August 31, 2020 NHL’s clinic related patient flow has met and exceeded 75% of pre-COVID-19 shutdown levels. In addition, as of August 31, 2020, NHL’s eldercare related revenue for the fiscal year 2020 fourth quarter exceeds 90% compared to eldercare related revenue for the fiscal year 2019 fourth quarter. As of August 31, 2020, the Company has 73 full-time employees and 37 part-time employees. Based on no additional “lockdowns” or new material directives are implemented limiting the Company’s ability to provide both its clinic and eldercare community related services, for fiscal year 2021 the Company projects a steady month-over-month increase as (i) recommended guidelines for patient-clinician on-site interaction are eased, and (ii) more overall movement restrictions are reduced and people are more comfortable in public spaces. The ultimate impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. The full long-term financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition, and results of operations. The measures taken to date will impact the Company’s fiscal year 2021 business and potentially beyond. Management expects that all of its business segments, across all of its geographies, will be impacted to some degree, but the significance of the full impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. Basis of Presentation The accompanying consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”). Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income August 31, August 31, 2020 2019 Period end: CAD to USD exchange rate $ 0.7674 $ 0.7507 Average period: CAD to USD exchange rate $ 0.7435 $ 0.7546

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to useful lives of non-current assets, impairment of non-current assets, allowance for doubtful accounts, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Novomerica, Novo Healthnet Rehab Limited, Novo Assessments Inc., an 80% controlling interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL, and a 70% controlling interest in Novo Earth Therapeutics Inc. (currently inactive). All the Company’s subsidiaries are incorporated under the laws of the Province of Ontario or New Brunswick, Canada. All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive loss. Cash Equivalents For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2020 and 2019, the allowance for uncollectible accounts receivable was $518,031 and $471,566, respectively. Property and Equipment Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Leasehold improvements 5 years Clinical equipment 5 years Computer equipment 3 years Office equipment 5 years Furniture and fixtures 5 years Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Intangible Assets The Company’s intangible assets consist of land use rights, a software license and intellectual property which will be amortized over 50 (the lease period), 7 and 7 years, respectively. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2020 and 2019, the Company believes there was no impairment of its intangible assets. Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. during the fiscal year ended August 31, 2017, Executive Fitness Leaders during the fiscal year ended August 31, 2018 and Action Plus Physiotherapy Rockland during the fiscal year ended August 31, 2019. Based on its review at August 31, 2020, the Company believes there was no impairment of its goodwill. As of August 31, 2019, the Company performed the required impairment reviews and determined that an impairment charge of $188,650 related to the goodwill for APKA Health, Inc was necessary. The impairment was determined based on the fair value of the acquired business, which was estimated based on a discounted cash flow valuation model and the projected future cash flows of the underlying business. Summary of changes in goodwill by acquired businesses is as follows: APKA EFL Rockland Total Balance, August 31, 2018 $ 382,350 $ 221,763 $ - $ 604,113 Goodwill acquired with purchase of assets - - 220,059 220,059 Impairment of goodwill (188,650 ) - - (188,650 ) Foreign currency translation adjustment (6,025 ) (4,060 ) (2,356 ) (12,441 ) Balance, August 31, 2019 $ 187,675 $ 217,703 $ 217,703 $ 623,081 Foreign currency translation adjustment 4,175 4,843 4,843 13,861 Balance, August 31, 2020 $ 191,850 $ 222,546 $ 222,546 $ 636,942 Acquisition Deposits The Company has signed letters of understanding with potential acquisition candidate(s) which includes refundable acquisition deposits totaling $383,700 and $716,688 as of August 31, 2020 and 2019, respectively. During the year ended August 31, 2020, the Company wrote off an acquisition deposit of $344,521 which is considered impaired since the acquiree has been dissolved and is no longer in business. Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and equivalents, accounts receivable, other receivables, accounts payable, and due to related parties, the carrying amounts approximate their fair values due to their short term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging As of August 31, 2020 and 2019, respectively, the Company did not identify any financial assets and liabilities required to be presented on the balance sheet at fair value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs. Revenue Recognition ASU No. 2014-09, Revenue from Contracts with Customers Topic 606. Topic 605, Revenue Recognition Revenue from providing healthcare and healthcare related services are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services - gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,199,696 and $1,138,919 at August 31, 2020 and 2019, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the consolidated balance sheet. Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases Leases In June 2016, the FASB issued ASU 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At August 31, 2020 and 2019, the amount due to related parties was $528,213 and $920,083, respectively, of which $458,550 are non-interest bearing, $22,084 bears interest at 6% per annum, and $47,579 bears interest at 13.75% per annum. The Company leased office space from a related party on a month-to-month basis with monthly lease payments of $1,487. The lease was terminated on May 31, 2020. On July 21, 2020, a related party converted $226,363 of outstanding principal and accrued interest into 150,909 shares of the Company’s common stock. The per share price used for the conversion of this debt was $1.50. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $267,768. The remaining principal balance of debentures to related parties at August 31, 2020 was $952,058.

Accounts Receivables, Net

Accounts Receivables, Net	12 Months Ended
	Aug. 31, 2020
Receivables [Abstract]
Accounts Receivables, Net	Note 4 – Accounts Receivables, net Accounts receivables, net at August 31, 2020 and 2019 consisted of the following: 2020 2019 Trade receivables $ 1,948,520 $ 1,631,036 Amounts earned but not billed 301,943 304,059 2,250,463 1,935,095 Allowance for doubtful accounts (518,031 ) (471,566 ) Accounts receivable, net $ 1,732,432 $ 1,463,529

Other Receivables

Other Receivables	12 Months Ended
	Aug. 31, 2020
Receivables [Abstract]
Other Receivables	Note 5 – Other Receivables Other receivables at August 31, 2020 and 2019 consisted of the following: 2020 2019 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019. (currently in default; if the receivable is not repaid, the Company plans to foreclose on the clinic that secures this receivable) $ 287,775 $ 281,513 Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020 - 30,028 Advance to corporation; accrues interest at 12% per annum; unsecured; due December 31, 2020 76,740 75,070 Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2021 225,924 225,924 Advance to corporation; accrues interest at 10% per annum; secured by property and other assets; due December 31, 2020 - 750,700 Total other receivables 590,439 1,363,235 Current portion (302,664 ) (300,994 ) Long-term portion $ 287,775 $ 1,062,241 During the year ended August 31, 2020, the Company settled another receivable for less than the amount due and recognized a loss on settlement of $74,360. During the year ended August 31, 2020 and 2019, the Company wrote off a note receivable for $29,744 and $56,595, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Aug. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 – Property and Equipment Property and equipment at August 31, 2020 and 2019 consisted of the following: 2020 2019 Leasehold improvements $ 465,857 $ 453,233 Clinical equipment 301,337 285,307 Computer equipment 23,921 23,133 Office equipment 29,229 28,593 Furniture and fixtures 39,760 38,895 860,104 829,161 Accumulated depreciation (506,444 ) (418,973 ) Total $ 353,660 $ 410,188 Depreciation expense for the years ended August 31, 2020 and 2019 was $75,726 and $97,143, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Aug. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 7 – Intangible Assets Intangible assets at August 31, 2020 and 2019 consisted of the following: 2020 2019 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 758,567 Intellectual property 5,248,000 - 27,992,798 22,358,567 Accumulated amortization (1,369,350 ) - Total $ 26,623,448 $ 22,358,567 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Years Ending August 31, 2021 $ 1,345,257 2022 1,345,257 2023 1,345,257 2024 1,345,257 2025 1,345,257 Thereafter 19,897,163 Total $ 26,623,448 On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell (the “Acquisition”), proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada (the “Intellectual Property”). Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 8,000,000 shares of restricted common stock of the Company valued at $5,248,000. On February 26, 2019, the Company and NHL entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”), pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”). Pursuant to the terms of the Cloud DX License, Cloud DX also agreed to sell, and NHL agreed to purchase, 4,000 fully functional Pulsewave PAD 1A USB blood pressure monitor devices bundled with the perpetual license discussed above (the “Bundled Devices”). The Cloud DX License granted to NHL and its majority-owned subsidiaries, holding companies, divisions and affiliates, other than physiotherapy clinics owned and operated by Closing The Gap Healthcare Inc., the right to use and sub-license the Licensed Software and re-sell the Bundled Devices pursuant to the terms of the Cloud DX License in the physical therapy clinic marketplace in North America in exchange for the purchase price as set forth below: ● Upon the closing, the Company issued 458,349 restricted shares of its common stock having a value (as calculated as set forth in the Cloud DX License) of CAD$1,000,000 (approximately $758,567 as of February 26, 2019), and ● Cloud DX agreed to invoice CAD$250,000 (approximately $189,642 as of February 26, 2019) to NHL based on the following deliverables, and paid on the following schedule: Cloud DX deliverable Novo payment (terms: Net 15) Heart Friendly Program launches in Clinic #1 CAD$50,000 (approximately $37,929 as of February 26, 2019) Novo-branded Android app delivered as APK file CAD$35,000 (approximately $26,550 as of February 26, 2019) Novo-branded Clinical portal website delivered CAD$35,000 (approximately $26,550 as of February 26, 2019) Pulsewave PAD-1A devices – 1st delivery CAD$20,000 (approximately $15,171 as of February 26, 2019) Marketing services / materials delivered CAD$25,000 (approximately $18,964 as of February 26, 2019) Cloud DX hires dedicated Novo support FTE CAD$85,000 (approximately $64,478 as of February 26, 2019) On March 9, 2020, the Company and NHL entered into that certain First Amendment to Cloud DX Perpetual Software License Agreement (the “Cloud DX Amendment”) with Cloud DX, effective March 6, 2020, pursuant to which the parties thereto agreed that the CAD$250,000 (approximately $186,231 as of March 6, 2020) that was to be paid by NHL based on the above deliverables would be paid as a one-time payment of 465,578 restricted shares of Company common stock. In addition, pursuant to the terms of the Cloud DX Amendment, the parties agreed to settle a $200,000 fee owed by NHL to Cloud DX through payment of 500,000 restricted shares of Company common stock. Except as set forth in the Cloud DX Amendment, the remaining terms and conditions of the Cloud DX License remain in full force and effect. There was no amortization expense during 2020 and 2019 as the listed intangible assets have not been placed in service.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Aug. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	Note 8 – Accrued Expenses Accrued expenses at August 31, 2020 and 2019 consisted of the following: 2020 2019 Accrued liabilities $ 37,457 $ 59,661 Accrued payroll 117,823 115,912 Other 39,428 30,211 $ 194,708 $ 205,784

Government Loans and Note Payab

Government Loans and Note Payable and Goverment Subsidy	12 Months Ended
	Aug. 31, 2020
Government Loans And Note Payable And Goverment Subsidy
Government Loans and Note Payable and Government Subsidy	Note 9 – Government Loans and Note Payable and Government Subsidy Governmental loans and note payable at August 31, 2020 and 2019 consisted of the following: 2020 2019 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months and accrues interest at 1% per annum. The Company expects some or all of this loan to be forgiven as provided by in the CARES Act. $ 21,900 $ - Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 61,392 - $ 83,292 $ - (A) The Government of Canada launched the Canada Emergency Business Account loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$80,000 loan (US$61,392 at August 31, 2020), which is unsecured, non-interest bearing and due on or before December 31, 2022. If the loan amount is paid on or before December 31, 2022, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2022, the Early Payment Credit will not apply. Government Subsidy During the year ended August 31, 2020, the Government of Canada announced the Canada Emergency Wage Subsidy (“CEWS”) for Canadian employers whose businesses were affected by the COVID-19 pandemic. The CEWS provides a subsidy of up to 75% of eligible employees’ employment insurable remuneration, subject to certain criteria. Accordingly, the Company applied for the CEWS to the extent it met the requirements to receive the subsidy and during the year ended August 31, 2020, recorded a total of approximately $645,000 in government subsidies as a reduction to the associated wage costs recorded in cost of revenues and general and administrative expenses in the consolidated statement of operations and comprehensive loss.

Debentures, Related Parties

Debentures, Related Parties	12 Months Ended
	Aug. 31, 2020
Debt Disclosure [Abstract]
Debentures, Related Parties	Note 10 – Debentures, related parties On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 (approximately $6,225,163 on September 30, 2013) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019. On September 27, 2019, the debenture holders agreed to extend the due date to September 30, 2021. On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined as the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $267,768. At August 31, 2020 and 2019, the amount of debentures outstanding was $952,058 and $1,201,591, respectively.

Leases

Leases	12 Months Ended
	Aug. 31, 2020
Leases [Abstract]
Leases	Note 11 – Leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. Effective March 1, 2019, the Company adopted the provision of ASC 842 Leases. The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2020 and 2019: 2020 2019 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,810,556 $ 3,004,017 Total lease assets $ 2,810,556 $ 3,004,017 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 563,793 $ 508,305 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,266,887 2,500,004 Total lease liability $ 2,830,680 $ 3,008,309 Lease obligations at August 31, 2020 consisted of the following: Years Ending August 31, 2021 $ 802,214 2022 655,913 2023 590,196 2024 390,836 2025 315,539 2026 298,134 Thereafter 510,228 Total payments 3,563,060 Amount representing interest (732,380 ) Lease obligation, net 2,830,680 Less lease obligation, current portion (563,793 ) Lease obligation, long-term portion $ 2,266,887 The lease expense for the year ended August 31, 2020 was $788,272. The cash paid under operating leases during the year ended August 31, 2020 was $772,798. The lease expense for 2019 (since adoption of ASC 842) was $313,180. The cash paid under operating leases during 2019 (since adoption of ASC 842) was $308,868. At August 31, 2020, the weighted average remaining lease terms were 5.98 years and the weighted average discount rate was 8%.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Aug. 31, 2020
Equity [Abstract]
Stockholders' Deficit	Note 12 – Stockholders’ Deficit Convertible preferred stock The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. As of August 31, 2020 and 2019 there were 0 and 0 convertible preferred shares issued and outstanding, respectively. Common stock The Company has authorized 499,000,000 shares of $0.001 par value common stock. As of August 31, 2020 and 2019 there were 234,662,363 and 223,691,507 common shares issued and outstanding, respectively. During the fiscal year ended August 31, 2020, the Company: ● issued 8,000,000 restricted shares of common stock as consideration for the Intellectual Property Asset Purchase Agreement with a value of $5,248,000 based on the closing share price of $0.656 on the Agreement date of execution; ● issued 965,578 restricted shares of common stock as consideration for the License Agreement Amendment No. 1 with a value of $386,231 based on the closing share price of $0.40 on the execution date of the Agreement Amendment No. 1; ● issued 150,909 restricted shares of common stock as consideration for payment in full of a related party loan debt with a value of CAD$304,321 (approximately $226,363 as of July 21, 2020) based on a per share price of $1.50; ● issued 1,000,000 restricted shares of common stock as consideration for general financial advisory, investment banking and digital marketing services valued at $340,000, The fair value was determined based on the market price of the Company’s common stock on the date of grant; ● issued 500,000 S-8 shares, from the Company’s 2018 Incentive Plan, to an independent contractor as consideration for professional management consulting service valued at $250,000, The fair value was determined based on the market price of the Company’s common stock on the date of grants; and ● issued 354,369 restricted shares of common stock for cash proceeds of $113,399. During the fiscal year ended August 31, 2019, the Company issued: ● 12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate ● 458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567 ● 84,558 restricted shares of common stock as consideration for an Asset Purchase Agreement based on a per share price of $1.13 with a value of $95,550 ● 3,266,857 restricted shares of common stock for cash proceeds of $3,250,366 Stock Options and Warrants On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. During 2020 and 2019, the Company did not grant any awards under the 2015 Plan. As of August 31, 2018, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan. On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “2018 Plan”). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for the grant of stock options and the issuance of restricted stock, stock appreciation rights, phantom stock and performance awards to officers, directors, employees and eligible consultants to the Company or its subsidiaries. As of August 31, 2020, the 2018 Plan has 9,375,000 shares are available for award. The following is a summary of stock option/warrant activity: Weighted Weighted Average Options/ Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2018 10,030,000 0.30 4.56 $ 7,045,500 Granted 75,000 0.95 Forfeited (10,000 ) 2.00 Exercised - Outstanding, August 31, 2019 10,095,000 0.30 3.58 $ 1,141,500 Granted 7,750,000 0.30 Forfeited - Exercised - Outstanding, August 31, 2020 17,845,000 0.22 4.09 $ 3,173,800 Exercisable, August 31, 2020 17,845,000 $ 0.22 4.09 $ 3,173,800 The exercise price for options/warrants outstanding at August 31, 2020: Outstanding and Exercisable Number of Options/ Exercise Warrants Price 10,045,000 $ 0.16 7,750,000 0.30 50,000 0.50 17,845,000 For options granted during the fiscal year ended August 31, 2020 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.30 and the weighted-average exercise price of such options/warrants was $0.30. No options were granted during the fiscal year ended August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant. For options granted during the fiscal year ended August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ended August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant. The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $2,265,211 and $70,846 during the years ended August 31, 2020 and 2019, respectively. At August 31, 2020, the unamortized stock option expense was $0. The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows: Years Ended August 31, 2020 2019 Risk-free interest rate 0.21 % 2.78 % Expected life of the options 2.5 years 3.5 years Expected volatility 281 % 294 % Expected dividend yield 0 % 0 % During the year ended August 31, 2020, the Company re-priced the exercise price of 4,495,000 options to $0.16 and extended the expiration date of 4,370,000 options by two years. The change in fair value between the options using the original terms and the options using the new expiration dates and exercise prices was $62,822 which has been recorded as expense in the accompanying consolidated statements of operations and comprehensive loss.

Income Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes The Company’s Canadian subsidiaries are subject to the income tax laws of the Province of Ontario and the country of Canada. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of August 31, 2020 and 2019 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. The current and deferred income tax expenses for the year ended August 31, 2020 and 2019 were $nil. A reconciliation of the differences between the effective and statutory income tax rates are as follows: Year Ended August 31, 2020 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (232,991 ) $ (4,682,163 ) $ (4,915,154 ) Expected income tax benefit (61,743 ) -26.5 % (1,264,184 ) -27.0 % (1,325,927 ) Stock based compensation - 0.0 % 787,869 16.8 % 787,869 Change in valuation allowance 61,743 26.5 % 476,315 10.2 % 538,058 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2019 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax income (loss) $ 8,752 $ (412,331 ) $ (403,579 ) Expected income tax expense (benefit) 2,319 -26.5 % (111,329 ) -27.0 % (109,010 ) Stock based compensation - 0.0 % 19,128 4.6 % 19,128 Change in valuation allowance (2,319 ) 26.5 % 92,201 22.4 % 89,882 $ - 0.0 % $ - 0.0 % $ - 0.0 % At August 31, 2020 and 2019, the significant components of the deferred tax assets are summarized below: 2020 2019 Deferred income tax asset Net operating loss carryforwards $ 2,913,805 $ 2,126,745 Total deferred income tax asset 2,913,805 2,126,745 Less: valuation allowance (2,913,805 ) (2,126,745 ) Total deferred income tax asset $ - $ - The valuation allowance for the years ended August 31, 2020 and 2019 increased by $787,060 and $51,708, respectively. The increase in 2020 was the result of the Company generating additional net operating losses. The increase in 2019 was the result of the Company generating additional net operating losses offset by a decrease resulting from the reduction of the federal income tax rate from 34% to 21% enacted in 2017, effective in 2018. The Company has recorded as of August 31, 2020 and 2019 a valuation allowance of $2,913,805 and $2,126,745, respectively, as it believes that it is more likely than not that the deferred tax assets will not be realized in future years. Management has based its assessment on the Company’s lack of profitable operating history. The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of August 31, 2020 and 2019. The Company has net operating loss carry-forward of approximately $3,248,000 and $4,397,000 in the United States and Canada, respectively. The use of the net operating losses in the United States may be significantly limited due to Internal Revenue Code section 382. The 2020, 2019 and 2018 tax years are still subject to audit.

Acquisition of Assets

Acquisition of Assets	12 Months Ended
	Aug. 31, 2020
Business Combinations [Abstract]
Acquisition of Assets	Note 14 – Acquisition of Assets On January 8, 2019, the Company and 2478659 Ontario Ltd., an Ontario Canada corporation with offices in Ontario Canada (“247”), entered into an Agreement of Transfer and Assignment (“JV Assignment”), pursuant to which the Company assumed all rights and obligations provided for in a Joint Venture Agreement, executed January 7, 2019, between 247 and Kainai Cooperative, a cooperative organized under the laws of Alberta, Canada with offices in Cardston, Alberta, Canada (“KA”). The JV Agreement provides for farming and greenhouse agricultural development, to include supporting infrastructure, of both hemp and medical cannabis crops on approximately 275,000 acres of Canadian prairie lands for a minimum of 50 years. Under the terms of the JV Assignment, 247 was issued 12,000,000 restricted shares of the Company’s common stock having a value of $21,600,000, as of February 26, 2019. The shares were issued on January 30, 2019. The underlying assets had no previous business operations; therefore, pro forma financial statements are not presented. On February 26, 2019, the Company and Novo Healthnet Limited entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX, Inc. (“Cloud DX”), a medical device company operating in the United States and Canada that develops both hardware and related software for Remote Patient Monitoring Medical Technology Platform and Chronic Care Management. Under the terms of the Cloud Dx License, Cloud Dx was issued 458,349 restricted shares of the Company’s common stock having a value of CAD$1,000,000 (approximately $758,567 as of February 26, 2019). The shares were issued on March 4, 2019. On July 22, 2019, the Company, NHL and Societe Professionnelle de Physiotherapie M Dignard carrying on business as Action Plus Physiotherapy Plus Rockland “APPR”), located in Rockland Ontario Canada, entered into an Asset Purchase Agreement, pursuant to which the Company acquired substantially all of the business assets of Action Plus Physiotherapy Rockland in exchange for an aggregate purchase price of CAD$300,000. Per the terms of the Asset Purchase Agreement, APPR was issued 84,558 restricted shares of common stock having a value of CAD$125,000 (approximately $95,550 as of July 19, 2019); and, was paid a cash amount of CAD$175,000 (approximately $132,055 as of July 22, 2019). The shares were issued on July 26, 2019. The purchase price was allocated to goodwill of $220,059 (CAD$290,000), to equipment of $6,791 (CAD$9,000) and to inventory of $755 (CAD$1,000). The purchase of these assets was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Aug. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Subsequent Events

Subsequent Events	12 Months Ended
	Aug. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 16 – Subsequent Events On September 24, 2020, the Company accepted a $92,000 subscription agreement from an accredited investor residing outside the United States for the sale of 219,048 restricted shares of the Company’s common stock, resulting in an effective price per share of $0.42. The shares were issued on September 24, 2020. On October 20, 2020, the Company executed a Statement of Work Agreement (“SOW”) for marketing and public relations services over a 6-month term. As consideration for payment of services provided for in the SOW, the Company (i) issued 150,000 restricted shares of common stock; and (ii) will pay $8,000 per month. The shares were issued on October 22, 2020. On October 21, 2020, the Company executed a Consulting and Services Agreement (“CSA”) for marketing and strategic planning services over a 6-month term. As consideration for payment of services provided for in the CSA, the Company (i) issued 500,000 restricted shares of common stock; and (ii) will pay $6,000 per month, and (iii) will pay a one-time $17,000 fee at the end of the 6-month term. The shares were issued on October 26, 2020. On November 9, 2020, stockholders of the Company approved an amendment to the Company’s Articles of Incorporation, as amended (the “Articles”), to effect a reverse stock split of the Company’s outstanding shares of common stock, at a ratio of no less than 1-for-5 and no more than 1-for-10, with such ratio to be determined by the sole discretion of the Board of Directors, with any fractional shares being rounded up to the next higher whole shares (the “Reverse Split”). On November 9, 2020, the Company’s Board of Directors approved the Reverse Split in a ratio of 1-for-10 and the Company filed a certificate of amendment to the Articles implementing the Reverse Split in a ratio of 1-for-10 effective November 30, 2020; provided, however, that in no event will the Reverse Split become effective until it has been processed by the Financial Industry Regulatory Authority (“FINRA”). On November 23, 2020, in order to change the effective date of the Reverse Split to December 10, 2020, the Company terminated the November 9, 2020 certificate of amendment and filed a new certificate of amendment to the Articles implementing the Reverse Split in a ratio of 1-for-10 effective December 10, 2020; provided however, that in no event will the Reverse Split become effective until it has been processed by FINRA. The Company expects that the Reverse Split in a ratio of 1-for-10 will be effective on or about December 10, 2020. On December 4, 2020, the Company temporarily delayed the Reverse Split. In order to delay the effective date of the Reverse Split, the Company terminated the November 23, 2020 certificate of amendment and filed a new certificate of amendment to the Articles implementing the Reverse Split in a ratio of 1-for-10 effective January 29, 2021; provided, however, that in no event will the Reverse Split become effective until it has been processed by the Financial Industry Regulatory Authority.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to useful lives of non-current assets, impairment of non-current assets, allowance for doubtful accounts, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Novomerica, Novo Healthnet Rehab Limited, Novo Assessments Inc., an 80% controlling interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL, and a 70% controlling interest in Novo Earth Therapeutics Inc. (currently inactive). All the Company’s subsidiaries are incorporated under the laws of the Province of Ontario or New Brunswick, Canada. All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.
Noncontrolling Interest	Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive loss.
Cash Equivalents	Cash Equivalents For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2020 and 2019, the allowance for uncollectible accounts receivable was $518,031 and $471,566, respectively.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Leasehold improvements 5 years Clinical equipment 5 years Computer equipment 3 years Office equipment 5 years Furniture and fixtures 5 years
Long-Lived Assets	Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment
Intangible Assets	Intangible Assets The Company’s intangible assets consist of land use rights, a software license and intellectual property which will be amortized over 50 (the lease period), 7 and 7 years, respectively. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2020 and 2019, the Company believes there was no impairment of its intangible assets.
Right-of-use Assets	Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. during the fiscal year ended August 31, 2017, Executive Fitness Leaders during the fiscal year ended August 31, 2018 and Action Plus Physiotherapy Rockland during the fiscal year ended August 31, 2019. Based on its review at August 31, 2020, the Company believes there was no impairment of its goodwill. As of August 31, 2019, the Company performed the required impairment reviews and determined that an impairment charge of $188,650 related to the goodwill for APKA Health, Inc was necessary. The impairment was determined based on the fair value of the acquired business, which was estimated based on a discounted cash flow valuation model and the projected future cash flows of the underlying business. Summary of changes in goodwill by acquired businesses is as follows: APKA EFL Rockland Total Balance, August 31, 2018 $ 382,350 $ 221,763 $ - $ 604,113 Goodwill acquired with purchase of assets - - 220,059 220,059 Impairment of goodwill (188,650 ) - - (188,650 ) Foreign currency translation adjustment (6,025 ) (4,060 ) (2,356 ) (12,441 ) Balance, August 31, 2019 $ 187,675 $ 217,703 $ 217,703 $ 623,081 Foreign currency translation adjustment 4,175 4,843 4,843 13,861 Balance, August 31, 2020 $ 191,850 $ 222,546 $ 222,546 $ 636,942
Acquisition Deposits	Acquisition Deposits The Company has signed letters of understanding with potential acquisition candidate(s) which includes refundable acquisition deposits totaling $383,700 and $716,688 as of August 31, 2020 and 2019, respectively. During the year ended August 31, 2020, the Company wrote off an acquisition deposit of $344,521 which is considered impaired since the acquiree has been dissolved and is no longer in business.
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and equivalents, accounts receivable, other receivables, accounts payable, and due to related parties, the carrying amounts approximate their fair values due to their shortterm maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging As of August 31, 2020 and 2019, respectively, the Company did not identify any financial assets and liabilities required to be presented on the balance sheet at fair value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs.
Revenue Recognition	Revenue Recognition ASU No. 2014-09, Revenue from Contracts with Customers Topic 606. Topic 605, Revenue Recognition Revenue from providing healthcare and healthcare related services are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services - gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share
Foreign Currency Transactions and Comprehensive Income	Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,199,696 and $1,138,919 at August 31, 2020 and 2019, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the consolidated balance sheet.
Statement of Cash Flows	Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases Leases In June 2016, the FASB issued ASU 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	12 Months Ended
	Aug. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	The following table details the exchange rates used for the respective periods: August 31, August 31, 2020 2019 Period end: CAD to USD exchange rate $ 0.7674 $ 0.7507 Average period: CAD to USD exchange rate $ 0.7435 $ 0.7546

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2020
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Assets	Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Leasehold improvements 5 years Clinical equipment 5 years Computer equipment 3 years Office equipment 5 years Furniture and fixtures 5 years
Schedule of Changes in Goodwill	Summary of changes in goodwill by acquired businesses is as follows: APKA EFL Rockland Total Balance, August 31, 2018 $ 382,350 $ 221,763 $ - $ 604,113 Goodwill acquired with purchase of assets - - 220,059 220,059 Impairment of goodwill (188,650 ) - - (188,650 ) Foreign currency translation adjustment (6,025 ) (4,060 ) (2,356 ) (12,441 ) Balance, August 31, 2019 $ 187,675 $ 217,703 $ 217,703 $ 623,081 Foreign currency translation adjustment 4,175 4,843 4,843 13,861 Balance, August 31, 2020 $ 191,850 $ 222,546 $ 222,546 $ 636,942

Accounts Receivables, Net (Tabl

Accounts Receivables, Net (Tables)	12 Months Ended
	Aug. 31, 2020
Receivables [Abstract]
Schedule of Accounts Receivables, Net	Accounts receivables, net at August 31, 2020 and 2019 consisted of the following: 2020 2019 Trade receivables $ 1,948,520 $ 1,631,036 Amounts earned but not billed 301,943 304,059 2,250,463 1,935,095 Allowance for doubtful accounts (518,031 ) (471,566 ) Accounts receivable, net $ 1,732,432 $ 1,463,529

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Aug. 31, 2020
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at August 31, 2020 and 2019 consisted of the following: 2020 2019 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019. (currently in default; if the receivable is not repaid, the Company plans to foreclose on the clinic that secures this receivable) $ 287,775 $ 281,513 Advance to corporation; non-interest bearing; unsecured; due not later than November 18, 2020 - 30,028 Advance to corporation; accrues interest at 12% per annum; unsecured; due December 31, 2020 76,740 75,070 Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2021 225,924 225,924 Advance to corporation; accrues interest at 10% per annum; secured by property and other assets; due December 31, 2020 - 750,700 Total other receivables 590,439 1,363,235 Current portion (302,664 ) (300,994 ) Long-term portion $ 287,775 $ 1,062,241

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Aug. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at August 31, 2020 and 2019 consisted of the following: 2020 2019 Leasehold improvements $ 465,857 $ 453,233 Clinical equipment 301,337 285,307 Computer equipment 23,921 23,133 Office equipment 29,229 28,593 Furniture and fixtures 39,760 38,895 860,104 829,161 Accumulated depreciation (506,444 ) (418,973 ) Total $ 353,660 $ 410,188

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Aug. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at August 31, 2020 and 2019 consisted of the following: 2020 2019 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 758,567 Intellectual property 5,248,000 - 27,992,798 22,358,567 Accumulated amortization (1,369,350 ) - Total $ 26,623,448 $ 22,358,567
Schedule of Expected Amortization Expense of Intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Years Ending August 31, 2021 $ 1,345,257 2022 1,345,257 2023 1,345,257 2024 1,345,257 2025 1,345,257 Thereafter 19,897,163 Total $ 26,623,448
Schedule of Software Deliverables and Payments	Cloud DX deliverable Novo payment (terms: Net 15) Heart Friendly Program launches in Clinic #1 CAD$50,000 (approximately $37,929 as of February 26, 2019) Novo-branded Android app delivered as APK file CAD$35,000 (approximately $26,550 as of February 26, 2019) Novo-branded Clinical portal website delivered CAD$35,000 (approximately $26,550 as of February 26, 2019) Pulsewave PAD-1A devices – 1st delivery CAD$20,000 (approximately $15,171 as of February 26, 2019) Marketing services / materials delivered CAD$25,000 (approximately $18,964 as of February 26, 2019) Cloud DX hires dedicated Novo support FTE CAD$85,000 (approximately $64,478 as of February 26, 2019)

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Aug. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at August 31, 2020 and 2019 consisted of the following: 2020 2019 Accrued liabilities $ 37,457 $ 59,661 Accrued payroll 117,823 115,912 Other 39,428 30,211 $ 194,708 $ 205,784

Government Loans and Note Pay_2

Government Loans and Note Payable and Goverment Subsidy (Tables)	12 Months Ended
	Aug. 31, 2020
Government Loans And Note Payable And Goverment Subsidy
Schedule of Governmental Loans and Note Payable	Governmental loans and note payable at August 31, 2020 and 2019 consisted of the following: 2020 2019 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months and accrues interest at 1% per annum. The Company expects some or all of this loan to be forgiven as provided by in the CARES Act. $ 21,900 $ - Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 61,392 - $ 83,292 $ - (A) The Government of Canada launched the Canada Emergency Business Account loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$80,000 loan (US$61,392 at August 31, 2020), which is unsecured, non-interest bearing and due on or before December 31, 2022. If the loan amount is paid on or before December 31, 2022, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2022, the Early Payment Credit will not apply.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Aug. 31, 2020
Leases [Abstract]
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2020 and 2019: 2020 2019 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,810,556 $ 3,004,017 Total lease assets $ 2,810,556 $ 3,004,017 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 563,793 $ 508,305 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,266,887 2,500,004 Total lease liability $ 2,830,680 $ 3,008,309
Schedule of Lease Obligations	Lease obligations at August 31, 2020 consisted of the following: Years Ending August 31, 2021 $ 802,214 2022 655,913 2023 590,196 2024 390,836 2025 315,539 2026 298,134 Thereafter 510,228 Total payments 3,563,060 Amount representing interest (732,380 ) Lease obligation, net 2,830,680 Less lease obligation, current portion (563,793 ) Lease obligation, long-term portion $ 2,266,887

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Aug. 31, 2020
Equity [Abstract]
Schedule of Stock Option and Warrant Activity	The following is a summary of stock option/warrant activity: Weighted Weighted Average Options/ Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2018 10,030,000 0.30 4.56 $ 7,045,500 Granted 75,000 0.95 Forfeited (10,000 ) 2.00 Exercised - Outstanding, August 31, 2019 10,095,000 0.30 3.58 $ 1,141,500 Granted 7,750,000 0.30 Forfeited - Exercised - Outstanding, August 31, 2020 17,845,000 0.22 4.09 $ 3,173,800 Exercisable, August 31, 2020 17,845,000 $ 0.22 4.09 $ 3,173,800
Schedule of Options and Warrants Outstanding and Exercisable	The exercise price for options/warrants outstanding at August 31, 2020: Outstanding and Exercisable Number of Options/ Exercise Warrants Price 10,045,000 $ 0.16 7,750,000 0.30 50,000 0.50 17,845,000
Schedule of Fair Value of Options Granted by Using Valuation Assumptions	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows: Years Ended August 31, 2020 2019 Risk-free interest rate 0.21 % 2.78 % Expected life of the options 2.5 years 3.5 years Expected volatility 281 % 294 % Expected dividend yield 0 % 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective and Statutory Income Tax Rates	A reconciliation of the differences between the effective and statutory income tax rates are as follows: Year Ended August 31, 2020 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (232,991 ) $ (4,682,163 ) $ (4,915,154 ) Expected income tax benefit (61,743 ) -26.5 % (1,264,184 ) -27.0 % (1,325,927 ) Stock based compensation - 0.0 % 787,869 16.8 % 787,869 Change in valuation allowance 61,743 26.5 % 476,315 10.2 % 538,058 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2019 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax income (loss) $ 8,752 $ (412,331 ) $ (403,579 ) Expected income tax expense (benefit) 2,319 -26.5 % (111,329 ) -27.0 % (109,010 ) Stock based compensation - 0.0 % 19,128 4.6 % 19,128 Change in valuation allowance (2,319 ) 26.5 % 92,201 22.4 % 89,882 $ - 0.0 % $ - 0.0 % $ - 0.0 %
Schedule of the Deferred Tax Assets	At August 31, 2020 and 2019, the significant components of the deferred tax assets are summarized below: 2020 2019 Deferred income tax asset Net operating loss carryforwards $ 2,913,805 $ 2,126,745 Total deferred income tax asset 2,913,805 2,126,745 Less: valuation allowance (2,913,805 ) (2,126,745 ) Total deferred income tax asset $ - $ -

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)	Dec. 19, 2019	Dec. 17, 2019	Jan. 30, 2019	Jan. 07, 2019	Apr. 25, 2018	Aug. 31, 2020	Aug. 31, 2019
Common stock issued in connection with reverse merger transaction							$ 95,550
Parent Company [Member]
Common stock issued in connection with reverse merger transaction						$ 6,904
Joint Venture Agreement [Member]
Number of restricted shares of common stock, shares							12,000,000
Number of restricted shares of common stock							$ 21,600,000
Asset Purchase Agreement [Member]
Number of restricted shares of common stock, shares		8,000,000					84,558
Number of restricted shares of common stock							$ 95,550
Turbine Truck Engines, Inc [Member]
State country name						Delaware
Date of incorporation						Nov. 27, 2000
NHL [Member] | Share Exchange Agreement [Member]
Number of restricted shares of common stock, shares					167,797,406
Percentage of common stock issued and outstanding					85.00%
Kainai [Member] | Joint Venture Agreement [Member]
Number of restricted shares of common stock, shares			12,000,000
Percentage joint venture description				Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai.
Intangible asset, useful life amortized over term				50 years
Number of restricted shares of common stock			$ 21,600,000
Novo Earth Therapeutics Inc [Member]
Controlling interest percentage	70.00%

Organization and Basis of Pre_4

Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) - CAD [Member]	Aug. 31, 2020	Aug. 31, 2019
Period End [Member]
Foreign currency exchange rate	0.7674	0.7507
Average Period [Member]
Foreign currency exchange rate	0.7435	0.7546

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Allowance for uncollectible accounts receivable	$ 518,031	$ 471,566
Impairment of its long-lived assets	$ 29,744	245,245
Lease term	12 months
Refundable acquisition deposits	$ 383,700	716,688
Write off of acquisition deposit	$ 344,521
Potentially dilutive common stock options and warrants outstanding, shares	17,845,000	10,095,000
Translation gains	$ 1,199,696	$ 1,138,919
Lease payable obligation	2,830,680	$ 3,008,309
ASC 842 [Member]
Lease payable obligation	2,360,787
Cumulative effect on retained earnings
APKA Health, Inc. [Member]
Impairment of its long-lived assets	$ 188,650
Land Use Rights [Member]
Intangible asset, useful life amortized over term	50 years
Software License [Member]
Intangible asset, useful life amortized over term	7 years
Intellectual Property [Member]
Intangible asset, useful life amortized over term	7 years
Novo Healthnet Kemptville Centre, Inc. [Member]
Equity method investment, ownership percentage	80.00%
Novo Earth Therapeutics Inc [Member]
Equity method investment, ownership percentage	70.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)	12 Months Ended
	Aug. 31, 2020
Leasehold Improvements [Member]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property and equipment, estimated lives	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Changes in Goodwill (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Balance	$ 623,081	$ 604,113
Goodwill acquired with purchase of assets		220,059
Impairment of goodwill		(188,650)
Foreign currency translation adjustment	13,861	(12,441)
Balance	636,942	623,081
Rockland [Member]
Balance	217,703
Goodwill acquired with purchase of assets		220,059
Impairment of goodwill
Foreign currency translation adjustment	4,843	(2,356)
Balance	222,546	217,703
APKA [Member]
Balance	187,675	382,350
Goodwill acquired with purchase of assets
Impairment of goodwill		(188,650)
Foreign currency translation adjustment	4,175	(6,025)
Balance	191,850	187,675
EFL [Member]
Balance	217,703	221,763
Goodwill acquired with purchase of assets
Impairment of goodwill
Foreign currency translation adjustment	4,843	(4,060)
Balance	$ 222,546	$ 217,703

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jul. 21, 2020	Jul. 21, 2020	Aug. 31, 2020	Aug. 31, 2019
Due to related parties			$ 528,213	$ 920,083
Monthly lease payments			3,563,060
Related party debt, converted amount	$ 226,363
Debt converted, shares issued	150,909
Debt conversion price	$ 1.50	$ 1.50
Debenture due to related party	$ 267,768	$ 267,768	198,778	176,655
Debentures, outstanding			952,058	$ 1,201,591
Related Party [Member]
Monthly lease payments			1,487
Non-Interest Bearing [Member]
Due to related parties			458,550
6% Interest Rate [Member]
Due to related parties			22,084
13.75% Interest Rate [Member]
Due to related parties			$ 47,579

Accounts Receivables, Net - Sch

Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Receivables [Abstract]
Trade receivables	$ 1,948,520	$ 1,631,036
Amounts earned but not billed	301,943	304,059
Accounts receivable, gross	2,250,463	1,935,095
Allowance for doubtful accounts	(518,031)	(471,566)
Accounts receivable, net	$ 1,732,432	$ 1,463,529

Other Receivables (Details Narr

Other Receivables (Details Narrative) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Receivables [Abstract]
Other receivable loss on settlement	$ 74,360
Note receivable written off	$ 29,744	$ 56,595

Other Receivables - Schedule of

Other Receivables - Schedule of Other Receivables (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Total other receivables	$ 590,439	$ 1,363,235
Current portion	(302,664)	(300,994)
Long-term portion	287,775	1,062,241
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Total other receivables	287,775	281,513
Advance to Corporation One [Member]
Total other receivables		30,028
Advance to Corporation Two [Member]
Total other receivables	76,740	75,070
Advance to Corporation Three [Member]
Total other receivables	225,924	225,924
Advance to Corporation Four [Member]
Total other receivables		$ 750,700

Other Receivables - Schedule _2

Other Receivables - Schedule of Other Receivables (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Percentage of interest accrued per annum	8.00%	8.00%
Notes receivable due date	Mar. 1, 2019	Mar. 1, 2019
Advance to Corporation One [Member]
Notes receivable due date	Nov. 18, 2020	Nov. 18, 2020
Advance to Corporation Two [Member]
Percentage of interest accrued per annum	12.00%	12.00%
Notes receivable due date	Dec. 31, 2020	Dec. 31, 2020
Advance to Corporation Three [Member]
Percentage of interest accrued per annum	10.00%	10.00%
Notes receivable due date	Feb. 7, 2021	Feb. 7, 2022
Advance to Corporation Four [Member]
Percentage of interest accrued per annum	10.00%	10.00%
Notes receivable due date	Dec. 31, 2020	Dec. 31, 2020

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 75,726	$ 97,143

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Property and equipment, gross	$ 860,104	$ 829,161
Accumulated depreciation	(506,444)	(418,973)
Total	353,660	410,188
Leasehold Improvements [Member]
Property and equipment, gross	465,857	453,233
Clinical Equipment [Member]
Property and equipment, gross	301,337	285,307
Computer Equipment [Member]
Property and equipment, gross	23,921	23,133
Office Equipment [Member]
Property and equipment, gross	29,229	28,593
Furniture and Fixtures [Member]
Property and equipment, gross	$ 39,760	$ 38,895

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)	Mar. 06, 2020USD ($)shares	Mar. 06, 2020CAD ($)shares	Dec. 17, 2019USD ($)shares	Feb. 26, 2019USD ($)shares	Feb. 26, 2019CAD ($)shares	Aug. 31, 2020USD ($)shares	Aug. 31, 2019USD ($)
Proceeds from issuance of shares						$ 113,399	$ 3,250,366
Amortization expense
Intellectual Property Asset Purchase Agreement [Member]
Shares issued during period for intellectual property, shares | shares			8,000,000			8,000,000
Shares issued during period for intellectual property			$ 5,248,000			$ 5,248,000
Software License Agreement [Member] | Cloud DX, Inc. [Member]
Number of restricted shares of common stock | shares				458,349	458,349
Proceeds from issuance of shares				$ 758,567
Payments to acquire software license				$ 189,642
Software License Agreement [Member] | Cloud DX, Inc. [Member] | CAD [Member]
Proceeds from issuance of shares					$ 1,000,000
Payments to acquire software license					$ 250,000
Perpetual Software License Agreement [Member] | Cloud DX, Inc. [Member]
Number of restricted shares of common stock | shares	465,578	465,578
Payments to acquire software license	$ 186,231
Perpetual Software License Agreement [Member] | Cloud DX, Inc. [Member] | CAD [Member]
Payments to acquire software license		$ 250,000
Cloud DX Amendment [Member] | Novo Healthnet Limited, Inc [Member]
Number of restricted shares of common stock | shares	500,000	500,000
Payments to acquire software license	$ 200,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Intangible assets, gross	$ 27,992,798	$ 22,358,567
Accumulated amortization	(1,369,350)
Total	26,623,448	22,358,567
Land Use Rights [Member]
Intangible assets, gross	21,600,000	21,600,000
Software License [Member]
Intangible assets, gross	1,144,798	758,567
Intellectual Property [Member]
Intangible assets, gross	$ 5,248,000

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Expected Amortization Expense of Intangible Assets (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Intangible Assets - Schedule Of Expected Amortization Expense Of Intangible Assets
2021	$ 1,345,257
2022	1,345,257
2023	1,345,257
2024	1,345,257
2025	1,345,257
Thereafter	19,897,163
Total	$ 26,623,448	$ 22,358,567

Intangible Assets - Schedule _3

Intangible Assets - Schedule of Software Deliverables and Payments (Details) - Feb. 26, 2019 - Software License Agreement [Member] - Cloud DX, Inc. [Member]	USD ($)	CAD ($)
Payments to acquire software license	$ 189,642
Heart Friendly Program Launches in Clinic [Member]
Payments to acquire software license	37,929
Novo-Branded Android App [Member]
Payments to acquire software license	26,550
Novo-Branded Clinical Portal Website [Member]
Payments to acquire software license	26,550
Pulsewave PAD-1A Devices [Member]
Payments to acquire software license	15,171
Marketing Services / Materials Delivered [Member]
Payments to acquire software license	18,964
Novo Support FTE [Member]
Payments to acquire software license	$ 64,478
CAD [Member]
Payments to acquire software license		$ 250,000
CAD [Member] | Heart Friendly Program Launches in Clinic [Member]
Payments to acquire software license		50,000
CAD [Member] | Novo-Branded Android App [Member]
Payments to acquire software license		35,000
CAD [Member] | Novo-Branded Clinical Portal Website [Member]
Payments to acquire software license		35,000
CAD [Member] | Pulsewave PAD-1A Devices [Member]
Payments to acquire software license		20,000
CAD [Member] | Marketing Services / Materials Delivered [Member]
Payments to acquire software license		25,000
CAD [Member] | Novo Support FTE [Member]
Payments to acquire software license		$ 85,000

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Payables and Accruals [Abstract]
Accrued liabilities	$ 37,457	$ 59,661
Accrued payroll	117,823	115,912
Other	39,428	30,211
Accrued expenses	$ 194,708	$ 205,784

Government Loans and Note Pay_3

Government Loans and Note Payable and Government Subsidy (Details Narrative)	12 Months Ended
	Aug. 31, 2020USD ($)
Canada Emergency Wage Subsidy [Member] | Cost of Revenues and General and Administrative Expense [Member]
Government subsidies	$ 645,000

Government Loans and Note Pay_4

Government Loans and Note Payable and Government Subsidy - Schedule of Governmental Loans and Note Payable (Details) - USD ($)	Aug. 31, 2020		Aug. 31, 2019
Notes payable	$ 83,292
Notes Payable [Member]
Notes payable	21,900
Notes Payable One [Member]
Notes payable	$ 61,392	[1]
[1]	The Government of Canada launched the Canada Emergency Business Account loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$80,000 loan (US$61,392 at August 31, 2020), which is unsecured, non-interest bearing and due on or before December 31, 2022. If the loan amount is paid on or before December 31, 2022, 25% of the loan will be forgiven ("Early Payment Credit"). In the event that the Company does not repay 75% of such term debt on or before December 31, 2022, the Early Payment Credit will not apply.

Government Loans and Note Pay_5

Government Loans and Note Payable and Government Subsidy - Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2020USD ($)	Aug. 31, 2020CAD ($)	Aug. 31, 2019USD ($)
Loan amount	$ 83,292
Canada Emergency Business Account Loan [Member]
Loan amount	$ 61,392
Notes payable, due date	Dec. 31, 2022
Percentage of interest accrued per annum	25.00%
Debt description	If the loan amount is paid on or before December 31, 2022, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2022, the Early Payment Credit will not apply.
Canada Emergency Business Account Loan [Member] | CAD [Member]
Loan amount		$ 80,000

Debentures, Related Parties (De

Debentures, Related Parties (Details Narrative)	Sep. 30, 2020	Jul. 21, 2020USD ($)$ / sharesshares	Jul. 21, 2020USD ($)$ / shares	Sep. 27, 2019	Jan. 31, 2018USD ($)$ / sharesshares	Dec. 02, 2017	Aug. 31, 2020USD ($)	Aug. 31, 2019USD ($)	Sep. 30, 2013USD ($)	Sep. 30, 2013CAD ($)
Debentures, outstanding							$ 952,058	$ 1,201,591
Accrued interest							346,264	248,582
Debt converted, shares issued | shares		150,909
Debt conversion price | $ / shares		$ 1.50	$ 1.50
Repayment of related party debt		$ 267,768	$ 267,768				$ 198,778	$ 176,655
Five Debentures [Member]
Debentures, outstanding									$ 6,225,163
Debt interest rate									8.00%	8.00%
Debt due date	Sep. 30, 2016
Debt extended due date				Sep. 30, 2021		Sep. 30, 2019
Five Debentures [Member] | CAD [Member]
Debentures, outstanding										$ 6,402,512
Debentures [Member]
Debentures, outstanding					$ 3,894,809
Percentage of debt converted					75.00%
Accrued interest					$ 414,965
Debt converted, shares issued | shares					10,475,872
Debt conversion price | $ / shares					$ 0.4114
Debt conversion, description					The per share price used for the conversion of each debenture was $0.4114 which was determined as the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Operating leases expiration date	2028
Lease expense	$ 788,272
Cash paid under operating leases	$ 772,798
Weighted average remaining lease terms	5 years 11 months 23 days
Weighted average discount rate	8.00%
ASC 842 [Member]
Lease expense		$ 313,180

Leases - Schedule of Lease Rela

Leases - Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Leases [Abstract]
Operating lease assets	$ 2,810,556	$ 3,004,017
Total lease assets	2,810,556	3,004,017
Current liabilities- Operating lease liability	563,793	508,305
Noncurrent liabilities - Operating lease liability	2,266,887	2,500,004
Total lease liability	$ 2,830,680	$ 3,008,309

Leases - Schedule of Lease Obli

Leases - Schedule of Lease Obligations (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Leases [Abstract]
2021	$ 802,214
2022	655,913
2023	590,196
2024	390,836
2025	315,539
2026	298,134
Thereafter	510,228
Total payments	3,563,060
Amount representing interest	(732,380)
Lease obligation, net	2,830,680	$ 3,008,309
Less lease obligation, current portion	(563,793)	(508,305)
Lease obligation, long-term portion	$ 2,266,887	$ 2,500,004

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative)	Jul. 21, 2020USD ($)	Dec. 17, 2019USD ($)shares	Jan. 16, 2018shares	Sep. 08, 2015shares	Aug. 31, 2020USD ($)$ / sharesshares	Aug. 31, 2020CAD ($)shares	Aug. 31, 2019USD ($)$ / sharesshares	Aug. 31, 2018shares
Convertible preferred stock, shares authorized					1,000,000		1,000,000
Convertible preferred stock, par value | $ / shares					$ 0.001		$ 0.001
Convertible preferred stock, shares issued					0		0
Convertible preferred stock, shares outstanding					0		0
Common stock, shares authorized					499,000,000		499,000,000
Common stock, par value | $ / shares					$ 0.001		$ 0.001
Common stock, shares issued					234,662,363		223,691,507
Common stock, shares outstanding					234,662,363		223,691,507
Common stock issued for conversion of related party debt | $					$ 226,363
Common stock issued for services | $					590,000
Number of shares issued, value | $					$ 113,399		$ 3,250,366
Stock options granted weighted-average grant date fair value | $ / shares					$ .30		$ 0.94
Stock options/warrants weighted-average exercise price | $ / shares					$ .30		$ 0.95
Stock option expense | $					$ 2,265,211		$ 70,846
Unamortized stock option expense | $					$ 0
Number of options granted					17,845,000		10,095,000	10,030,000
Expense associated with modified stock option terms | $					$ 62,822
Restricted Common Stock [Member]
Number of shares issued							3,266,857
Number of shares issued, value | $							$ 3,250,366
Option 1 [Member]
Number of options granted					4,495,000
Exercise price, re-priced | $ / shares					$ 0.16
Option 2 [Member]
Number of options granted					4,370,000
Option term					2 years	2 years
2018 Incentive Plan [Member]
Number of common stock shares authorizes			10,000,000
Number of shares available for future grant					9,375,000
2018 Incentive Plan [Member] | Independent Contractor [Member]
Common stock issued for services, shares					500,000	500,000
Common stock issued for services | $					$ 250,000
2015 Incentive Compensation Plan [Member]
Number of shares available for future grant					4,987,500
2015 Incentive Compensation Plan [Member] | Maximum [Member]
Number of common stock shares authorizes				5,000,000
General Financial Advisory Investment Banking and Digital Marketing Services [Member]
Common stock issued for services, shares					1,000,000	1,000,000
Common stock issued for services | $					$ 340,000
Related Party Loan Debt [Member]
Common stock issued for conversion of related party debt, shares					150,909	150,909
Common stock issued for conversion of related party debt | $	$ 226,363
Shares issued price per share | $ / shares					$ 1.50
Related Party Loan Debt [Member] | CAD [Member]
Common stock issued for conversion of related party debt | $						$ 340,321
Intellectual Property Asset Purchase Agreement [Member]
Shares issued during period for intellectual property, shares		8,000,000			8,000,000	8,000,000
Shares issued during period for intellectual property | $		$ 5,248,000			$ 5,248,000
Closing price per share | $ / shares					$ 0.656
Licensing Agreement [Member]
Shares issued during period for intellectual property, shares					965,578	965,578
Shares issued during period for intellectual property | $					$ 386,231
Closing price per share | $ / shares					$ 0.40
Shares issued price per share | $ / shares							$ 1.655
Number of restricted shares							458,349
Proceeds from issuance of restricted shares | $							$ 758,567
Joint Venture Agreement [Member]
Shares issued price per share | $ / shares							$ 1.80
Number of restricted shares							12,000,000
Proceeds from issuance of restricted shares | $							$ 21,600,000
Asset Purchase Agreement [Member]
Shares issued price per share | $ / shares							$ 1.13
Number of restricted shares		8,000,000					84,558
Proceeds from issuance of restricted shares | $							$ 95,550

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Equity [Abstract]
Options/Warrants Outstanding, Beginning Balance	10,095,000	10,030,000
Options/Warrants Outstanding, Granted	7,750,000	75,000
Options/Warrants Outstanding, Forfeited		(10,000)
Options/Warrants Outstanding, Exercised
Options/Warrants Outstanding, Ending Balance	17,845,000	10,095,000
Options/Warrants Outstanding, Exercisable	17,845,000
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.30	$ .30
Weighted Average Exercise Price, Granted	.30	.95
Weighted Average Exercise Price, Forfeited		2
Weighted Average Exercise Price, Outstanding, Ending Balance	.22	$ 0.30
Weighted Average Exercise Price, Exercisable	$ .22
Weighted Average Remaining Contractual Life, Outstanding	4 years 1 month 2 days	4 years 6 months 21 days
Weighted Average Remaining Contractual Life, Exercisable	4 years 1 month 2 days	3 years 6 months 29 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$ 1,141,500	$ 7,045,500
Aggregate Intrinsic Value, Outstanding, Ending Balance	3,173,800	$ 1,141,500
Aggregate Intrinsic Value, Exercisable	$ 3,173,800

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details)	Aug. 31, 2020$ / sharesshares
Number of Options/Warrants, Outstanding	17,845,000
Number of Options/Warrants, Exercisable	17,845,000
Exercise Price Range One [Member]
Number of Options/Warrants, Outstanding	10,045,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares	$ 0.16
Number of Options/Warrants, Exercisable	10,045,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares	$ 0.16
Exercise Price Range Two [Member]
Number of Options/Warrants, Outstanding	7,750,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares	$ .30
Number of Options/Warrants, Exercisable	7,750,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares	$ .30
Exercise Price Range Three [Member]
Number of Options/Warrants, Outstanding	50,000
Number of Options/Warrants, Outstanding, Exercise Price | $ / shares	$ .50
Number of Options/Warrants, Exercisable	50,000
Number of Options/Warrants, Exercisable, Exercise Price | $ / shares	$ .50

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Equity [Abstract]
Risk-free interest rate	0.21%	2.78%
Expected life of the options	2 years 6 months	3 years 6 months
Expected volatility	281.00%	294.00%
Expected dividend yield	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current income tax expenses
Deferred income tax expenses
Increases in valuation allowances	787,060	51,708
Federal income tax rate			21.00%	34.00%
Deferred tax valuation allowances	2,913,805	2,126,745
Uncertain tax positions
Operating loss carry forward	$ 2,913,805	$ 2,126,745
United States [Member]
Federal income tax rate	27.00%	27.00%
Operating loss carry forward	$ 3,248,000
Canada [Member]
Federal income tax rate	26.50%	26.50%
Operating loss carry forward	$ 4,397,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective and Statutory Income Tax Rates (Details) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Combined statutory tax rate			21.00%	34.00%
Pretax income (loss)	$ (4,915,154)	$ (403,579)
Expected income tax expense (benefit)	(1,325,927)	(109,010)
Stock based compensation	787,869	19,128
Change in valuation allowance	538,058	89,882
Total
Total percentage	0.00%	0.00%
Canada [Member]
Combined statutory tax rate	26.50%	26.50%
Pretax income (loss)	$ (232,991)	$ 8,752
Expected income tax expense (benefit)	(61,743)	2,319
Stock based compensation
Change in valuation allowance	61,743	(2,319)
Total
Expected income tax expense (benefit), percentage	(26.50%)	(26.50%)
Stock based compensation, percentage	0.00%	0.00%
Change in valuation allowance, percentage	26.50%	26.50%
Total percentage	0.00%	0.00%
United States [Member]
Combined statutory tax rate	27.00%	27.00%
Pretax income (loss)	$ (4,682,163)	$ (412,331)
Expected income tax expense (benefit)	(1,264,184)	(111,329)
Stock based compensation	787,869	19,128
Change in valuation allowance	476,315	92,201
Total
Expected income tax expense (benefit), percentage	(27.00%)	(27.00%)
Stock based compensation, percentage	16.80%	4.60%
Change in valuation allowance, percentage	10.20%	22.40%
Total percentage	0.00%	0.00%

Income Taxes - Schedule of the

Income Taxes - Schedule of the Deferred Tax Assets (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 2,913,805	$ 2,126,745
Total deferred income tax asset	2,913,805	2,126,745
Less: valuation allowance	(2,913,805)	(2,126,745)
Total deferred income tax asset

Acquisition of Assets (Details

Acquisition of Assets (Details Narrative)	Dec. 17, 2019shares	Jul. 19, 2019USD ($)shares	Jul. 19, 2019CAD ($)shares	Feb. 26, 2019USD ($)shares	Feb. 26, 2019CAD ($)shares	Jan. 08, 2019ft²	Aug. 31, 2019USD ($)shares	Aug. 31, 2020USD ($)	Jul. 22, 2019USD ($)	Jul. 22, 2019CAD ($)	Aug. 31, 2018USD ($)
Purchase price of goodwill							$ 623,081	$ 636,942			$ 604,113
Agreement of Transfer and Assignment [Member]
Area of Canadian prairie lands | ft²						275,000
Agreement of Transfer and Assignment [Member] | Ontario Canada [Member]
Number of restricted shares of common stock | shares				12,000,000	12,000,000
Issuance of restricted stock value				$ 21,600,000
Agreement of Transfer and Assignment [Member] | Minimum [Member]
Minimum term period of canadian prairie lands						50 years
Software License Agreement [Member] | Cloud DX, Inc. [Member]
Number of restricted shares of common stock | shares				458,349	458,349
Issuance of restricted stock value				$ 758,567
Software License Agreement [Member] | Cloud DX, Inc. [Member] | CAD [Member]
Issuance of restricted stock value					$ 1,000,000
Asset Purchase Agreement [Member]
Number of restricted shares of common stock | shares	8,000,000						84,558
Issuance of restricted stock value							$ 95,550
Asset Purchase Agreement [Member] | Action Plus Physiotherapy Plus Rockland [Member]
Number of restricted shares of common stock | shares		84,558	84,558
Issuance of restricted stock value		$ 95,550
Payment for restricted stock issued value									$ 132,055
Purchase price of goodwill									220,059
Purchase price of equipment									6,791
Purchase price of inventory									$ 755
Asset Purchase Agreement [Member] | Action Plus Physiotherapy Plus Rockland [Member] | CAD [Member]
Issuance of restricted stock value			$ 125,000
Cash paid for acquisition of assets purchase price										$ 300,000
Payment for restricted stock issued value										175,000
Purchase price of goodwill										290,000
Purchase price of equipment										9,000
Purchase price of inventory										$ 1,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 04, 2020	Nov. 23, 2020	Nov. 09, 2020	Oct. 21, 2020	Oct. 20, 2020	Sep. 24, 2020	Aug. 31, 2020	Aug. 31, 2019
Number of shares issued, value							$ 113,399	$ 3,250,366
Subsequent Event [Member]
Reverse stock split, description	On December 4, 2020, the Company temporarily delayed the Reverse Split. In order to delay the effective date of the Reverse Split, the Company terminated the November 23, 2020 certificate of amendment and filed a new certificate of amendment to the Articles implementing the Reverse Split in a ratio of 1-for-10 effective January 29, 2021; provided, however, that in no event will the Reverse Split become effective until it has been processed by the Financial Industry Regulatory Authority.	On November 23, 2020, in order to change the effective date of the Reverse Split to December 10, 2020, the Company terminated the November 9, 2020 certificate of amendment and filed a new certificate of amendment to the Articles implementing the Reverse Split in a ratio of 1-for-10 effective December 10, 2020; provided however, that in no event will the Reverse Split become effective until it has been processed by FINRA. The Company expects that the Reverse Split in a ratio of 1-for-10 will be effective on or about December 10, 2020.	On November 9, 2020, stockholders of Novo Integrated Sciences, Inc. (the “Company”) approved an amendment to the Company’s Articles of Incorporation, as amended (the “Articles”), to effect a reverse stock split of the Company’s outstanding shares of common stock, at a ratio of no less than 1-for-5 and no more than 1-for-10, with such ratio to be determined by the sole discretion of the Board of Directors, with any fractional shares being rounded up to the next higher whole shares (the “Reverse Split”).
Subsequent Event [Member] | Statement of Work Agreement [Member]
Agreement term					6 months
Number of shares issued for services					150,000
Expense for services payable per month					$ 8,000
Subsequent Event [Member] | Consulting and Services Agreement [Member]
Agreement term				6 months
Number of shares issued for services				500,000
Expense for services payable per month				$ 6,000
Subsequent Event [Member] | Accredited Investor [Member]
Number of shares issued, value						$ 92,000
Number of shares issued						219,048
Shares issued price per share						$ .42